The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)
Sponsor: Boryung Pharmaceutical Co., Ltd
This PHASE3 trial investigates Hypertension and is currently completed. Boryung Pharmaceutical Co., Ltd leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2017 [monthly]
Completed PHASE3
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boryung Pharmaceutical Co., Ltd
- Daegu Catholic University Medical Center
- Dong-A medical center
- Gyeongsang National University Hospital
- Inje University
- Keimyung University
- Kosin University Gospel Hospital
- Kyungpook National University Hospital
- Pusan National University Hospital
- Pusan National University Yangsan Hospital
- Ulsan University Hospital
- Yeungnam University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .